News & Articles

Sutapa Ray and Paul Jenkins will be in San Francisco for BIO 2016 June 6 - 9. ...

Development of neurological and mental health drugs often requires pre-clinical testing in multiple pre-clinical models to demonstrate efficacy and safety and to elucidate mechanisms. Drug delivery to the central nervous system (CNS) to target neurological diseases is particularly problematic because the blood-brain barrier (BBB) prevents most compounds from reaching the...

Sutapa Ray will be attending the American Academy of Neurology 2016 Annual Meeting in Vancouver, BC April 15th - 21st. ...

On April 8th, Impel's director of business development, Paul Jenkins, will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Nasal Drug Delivery Conference in London. His presentation is on April 8 at 11:30 am in the Nose-to-brain Transport session....

On April 6 Impel CSO, John Hoekman will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Neurotech conference in Boston. His talk will be on April 6 at 10:30 at the Treatments for Alzheimer's and Cognitive Disorders session.  ...

The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. This novel treatment is a peptide that disrupts two dopamine receptors that bind at higher rates in the brains of people...